Developing evidence suggests that changes of plasma Aβ42/40 (ref. 3) and p-tau (refs. 5,17,1819–21) are elevated in preclinical disease and might act as an integral enrichment aid for AD trials. The gene discussed is MAPT; the disease is Alzheimer disease.